ClinicalTrials.gg
DrugRead study by study

Risvutatug rezetecan clinical trials

Also written HS-20093 and GSK5764227.

studies test it
32
open now
26
in phase 3
7
first study started
2021
ClinicalTrials.gov finds 11 studies for risvutatug rezetecan. How that becomes 32 here

Every study that search finds has been read, to see whether and how it gives risvutatug rezetecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 11Found by its intervention search · See all 11 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 9 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +24Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 35Give risvutatug rezetecan to participants
  4. −3Give it beside what is tested
  5. 32Test it: the count on this site

Get an email when these change. Save the risvutatug rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Risvutatug Rezetecan
6
HS-20093 for Injection
5
Ris-Rez
4
Risvutatug rezetecan (Ris-Rez)
2

Development codes

HS-20093
16
GSK5764227
8

Studies by the year they started

32 studies that test it; most in 2026 (11)

Studies that test risvutatug rezetecan, by start year
YearStudies
20211
20221
20232
20249
20258
202611

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
16
Phase 2
11
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 30 · Other 2

Hansoh BioMedical R&D Company (19) · GlaxoSmithKline (8) · Shanghai Hansoh Biomedical Co., Ltd (2) · University Health Network, Toronto (1) · Nader Sanai (1) · Jiangsu HengRui Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Adebrelimab (2) · Remzistotug (1) · Belrestotug (1) · Nelistotug (1) · Alveltamig (1) · Granulocyte Colony-Stimulating Factor (1) · Ivonescimab (1) · Zeprumetostat (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 5 most studied

New when their studies opened, with risvutatug rezetecan beside them; studies of each.

Reaching primary completion within a year · 6, 2 in phase 3

Studies that test risvutatug rezetecan, phase 3 first.

Studies

Open first, then newest update. How each study uses risvutatug rezetecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 32

See all 32 studies that test risvutatug rezetecan →

Tested on its own · 16 — no other medicine in its arm
Tested with established drugs · 8 — they are given beside it
Tested in a combination · 8 — another drug in the study is under test too
Beside a new treatment under test · 3 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with risvutatug rezetecan: nimotuzumab 1 · PARP1 Inhibitor HS-10502 1 · apatinib 1 · mocertatug rezetecan 1 · Platinum Compounds 1

Codes

What other systems call risvutatug rezetecan · ClinicalTrials.gg INT015531

  • UNII (FDA) 7T9A6CKG67RISVUTATUG REZETECANOne source FDA
  • NCI Thesaurus C187121Risvutatug RezetecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion